National Vision Holdings (EYE)
NASDAQConsumer DiscretionarySpecialty RetailSnapshot 2026-10-29
$16.64+7.63%
Close 2026-10-29 · 1-day change
NASDAQConsumer DiscretionarySpecialty RetailSnapshot 2026-10-29
Research Workspace
Put EYE beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Consumer Discretionary is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Revenue grows at least 5% annually: Comparison needs review.
View ThesisMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 1% on a typical day and fell roughly 48% in its worst 12-month stretch.
View RiskEYE’s investment case rests on strong performance and earnings growth, despite slowing revenue growth. Revenue growth eased from 6.6% to 2.5% year over year; Q2 FY2026 earnings beat consensus. EYE trades at 20× P/E versus a 15× peer median, though expectations look modest versus our view. The next-quarter miss probability is 28%, and the primary revenue-growth pillar needs review. Peer multiples imply a price about 23% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-29. EYE is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 12 analysts currently covering EYE (as of Oct 2026).
Based on 4 Wall Street analysts offering 12-month price targets for EYE in the last 4 months.
Continue this research
Compare EYE with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| EYE Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Consumer Discretionary (broad) — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put EYE next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Drive profitable growth with focus on higher-value customers
Building a vision care platform aligns with higher-value customer focus.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $16.64
The last 12 months of price, then the range of analyst 12-month targets from today’s $16.64.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Threatens: Drive profitable growth with focus on higher-value customers
Falling foot traffic impacts higher-value customer growth.
Advances: Increase revenue growth
Raised outlook indicates increased revenue growth potential.
Advances: Maintain cost discipline and improve operating margins
Margin expansion supports cost discipline and operating margins.
Advances: Increase revenue growth
Earnings call highlights positive revenue trends.
Threatens: Improve operating income
Narrowed comp outlook may hinder revenue growth.
Threatens: Increase revenue growth
Revenue fell short of estimates despite earnings beat.
Advances: Improve operating income
Raises income outlook positively impacts operating income.
